Bavarian Nordic raises 2022 annual guidance again after monkeypox vaccine deals
Reuters
Published May 30, 2022 03:03PM ET
(Reuters) - Danish biotechnology company Bavarian Nordic revised its annual guidance on Monday for a second time after signing supply contracts with several undisclosed countries for its Imvanex monkeypox vaccine.
Bavarian Nordic said vaccine deliveries would start immediately and added that it was in discussions with more countries regarding vaccine supply.
"We are pleased to assist more countries with supply of vaccines while we continue our dialogues with other governments to make vaccines available as fast as possible to mitigate the situation," CEO Paul Chaplin said in a statement.
Bavarian now expects 2022 revenue to be between 1.4 billion and 1.5 billion Danish crowns ($202.93 million and $217.43 million), up from earlier estimates of 1.3 billion to 1.5 billion.
The company also lifted its expectations for earnings before interest, tax and amortisation (EBITDA) to a loss of between 900 million and 1.1 billion crowns, up from previous guidance of loss of between 1 billion and 1.2 billion crowns.
Monkeypox is an infectious disease that is usually mild and is endemic in parts of west and central Africa. Global health officials have tracked more than 200 suspected and confirmed cases of the viral infection in 19 countries since early May.
The European Union last week announced that it was in talks to buy Bavarian Nordic's vaccine. The vaccine has official European approval for smallpox, although doctors can prescribe it off-label for monkeypox.
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.